Devices Radiology Oncology

 News Release - February 21, 2006

Six CT Laser Mammography Studies to be Included in European Congress of Radiology Scientific Sessions

Optical and Molecular Imaging Topics Strongly Represented

FORT LAUDERDALE, Fla., Feb. 21 (HSMN NewsFeed) -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS ) will exhibit at the European Congress of Radiology (ECR), in Vienna, Austria, March 3-7, in Expo C, #302. Clinical results from six studies relating to the CT Laser Mammography (CTLM®) system will be presented, providing many insights into applications for cancer detection, cancer staging, and following the course of cancer treatments.

The presentations reflect worldwide clinical and academic interest in a multidisciplinary approach that could improve the accuracy of conventional imaging methods. Molecular imaging approaches such as MRI and Nuclear Medicine are more frequently being used for breast imaging; these presentations demonstrate the clinical recognition that CTLM is gaining.

Presentations include:

Medical University of Vienna/Austria:
The value of CT-laser-mammography (CTLM) as an adjunct to mammography
and ultrasound in the diagnosis of breast cancer
Daniel Flory, MD, Thomas Helbich, MD, et al.

Gazi University Hospital, Ankara, Turkey:
Role of computer tomography laser mammography (CTLM) in the evaluation
of breast lesions
Aysegul Ozdemir, MD, et al.

University of Muenster Hospital, Muenster, Germany:
New developments in molecular imaging and breast cancer
Chris Bremer, MD

Catholic University, Rome, Italy:
Primer of breast optical imaging with computed tomography laser
mammography (CTLM)
Simona Gaudino, MD, et al.

Computed tomography laser mammography (CTLM) imaging in evaluation
response to neoadjuvant chemotherapy in breast cancer patient:
Correlation with mammogram, ultrasound, and Magnetic Resonance Imaging
Simona Gaudino, MD, et al.

Maria Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology, Gliwice, Poland:
Pictures of anatomical vessel structures can simulate malignant
angiogenesis in CT-laser mammography
Katarzyna Steinhof, MD, et al.

The studies address the use of CTLM in multidisciplinary breast cancer case assessments and methods to aid interpretation. In addition, the ability of CTLM to follow response to neoadjuvant chemotherapy in breast cancer patients was investigated.

"We are very pleased to have so many presentations on the CTLM system at ECR 2006. The presentation of clinical research from leading medical centers and researchers reinforces CTLM's role in managing breast cancer," stated Deborah O'Brien, Senior Vice President of Imaging Diagnostic Systems. "With the increasing interest in optical imaging and the number of publications and presented results, recognition of our laser breast imaging technology's current and future applications is clearly growing."

ECR is one of Europe's best-known radiological Congresses, attracting nearly 15,000 attendees from 90 countries. The Congress features scientific sessions and presentations as well as the technical exhibition.

The CTLM® system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Source: Imaging Diagnostic Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.